Membrane interactions of some catamphiphilic drugs and relation to their multidrug-resistance-reversing ability

Journal of Cancer Research and Clinical Oncology

Volumn 122, Issue 1, 1996, Pages 27-40

  Pajeva, I K ^a,b   Wiese, M ^a,c   Cordes, H P ^a   Seydel, J K ^a  

^a RESEARCH CENTER BORSTEL   (Germany)

^b BULGARIAN ACADEMY OF SCIENCES   (Bulgaria)

^c MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Artificial membranes; Catamphiphilic MDR modifiers; Drug membrane interactions; DSC and NMR measurements; MDR modulation mechanisms

Indexed keywords

AMIODARONE; ANTINEOPLASTIC AGENT; CHLORPROMAZINE; FLUNARIZINE; FLUPENTIXOL; IMIPRAMINE; LIDOCAINE; MEPACRINE; PHOSPHOLIPID; TRIFLUOPERAZINE; TRIFLUPROMAZINE; VERAPAMIL;

ANIMAL CELL; ARTICLE; ARTIFICIAL MEMBRANE; BREAST CARCINOMA; CALORIMETRY; CONTROLLED STUDY; HUMAN; HUMAN CELL; LEUKEMIA P 388; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PREVENTION; PRIORITY JOURNAL;

AMIODARONE; ANIMAL; ANTI-ARRHYTHMIA AGENTS; BREAST NEOPLASMS; CALORIMETRY, DIFFERENTIAL SCANNING; COMPARATIVE STUDY; DOPAMINE ANTAGONISTS; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUPENTHIXOL; HETEROCYCLIC COMPOUNDS; HUMAN; LEUKEMIA P388; MAGNETIC RESONANCE SPECTROSCOPY; MEMBRANES, ARTIFICIAL; MICE; PHOSPHATIDYLCHOLINES; PHOSPHATIDYLSERINES; SUPPORT, NON-U.S. GOV'T; VERAPAMIL;

EID: 0029655680     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01203070     Document Type: Article

References (23)

1. Aftab D, Ballas LM, Loomis CR, Hait WN (1991) Structure-activity relationships of phenothiazines and related drugs for inhibition of protein kinase C. Mol Pharmacol 40:798-805
2. Alon N, Busche R, Tümmler B, Riordan JK (1991) Membrane lipids of multidrug resistance cells: chemical composition and physical state. In: Roninson IB (ed) Molecular and cellular biology of multidrug resistance in tumour cells. Plenum, New York, London, pp 263-276
3. Awasthi S, Sharma R, Awasthy YC, Belli JA, Frenkel P (1992) The relationship of doxorubicin binding to membrane lipids with drug resistance. Cancer Lett 63:109-116
4. Bates SE, Lee JS, Dickstein B, Spolyar M, Fojo AT (1993) Differential modulation of P-glycoprotein transport by protein kinase inhibition. Biochemistry 32:9156-9164
5. Beck WT (1991) Drug accumulation and binding in P-glyco-protein-associated multidrug resistance. In: Roninson IB (ed) Molecular and cellular biology of multidrug resistance in tumour cells. Plenum, New York, London, pp 215-228
6. Beck WT, Qian X (1992) Photoaffinity substrates for P-glycoprotein. Biochem Pharmacol 43:89-93
7. Bell RM, Burns DJ (1991) Lipid activation of protein kinase C. J Biol Chem 266:4661-4664
8. Blobe GC, Sachs CW, Khan WA, Fabbro D, Stabel S, Wetsel WC, Obeid LM, Fine RL, Hannun YA (1993) Selective regulation of expression of protein kinase C (PKC) isoenzymes in multidrug resistant MCF-7 cells. Functional significance of enhanced expression of PKCα. J Biol Chem 268:658-664
9. Boer R, Schödl A, Haas S (1994) Inhibition of rhodamine-123 efflux and modulation of rhodamine-123 accumulation in CCRF VCR1000 cells by dexniguldipine-HCl and other chemo-sensitizers. Anti Cancer Drugs 5[Suppl 1]:20
10. Callaghan R, Stafford A, Epand R (1993) Increased accumulation of drugs in a multidrug resistant cell line by alteration of membrane biophysical properties. Biochim Biophys Acta 1175:277-282
11. Chambers T, Zheng B, Kuo JK (1992) Regulation by phorbol esters and protein kinase C inhibitors, and by protein phosphatase inhibitor (okadaic acid) of P-glycoprotein phosphorylation and relationship to drug accumulation in multidrug resistant human KB cells. Mol Pharmacol 41:1008-1015
12. Chaudhary PM, Roninson IB (1992) Activation of MDR1 (P-glycoprotein) gene expression in human cells by protein kinase C agonists. Oncol Res 4:281-290
13. Cornwell MM, Pastan I, Gottesman MM (1991) Binding of drugs and ATP by P-glycoprotein and transport of drugs by vesicles from human multidrug-resistant cells. In: Roninson IB (ed) Molecular and cellular biology of multidrug resistance in tumour cells. Plenum, New York, London, pp 229-242
14. De Wolf FA, Staflhorst RWHM, Smits H-P, Onwezen MF, Kruijff B de (1993) Role of anionic phospholipids in the interaction of doxorubicin and plasma membrane vesicles: drug binding and structural consequences in bacterial systems. Biochemistry 32:6688-6695
15. Fine RL, Patel J, Chabner BA (1988) Phorbol esters induce multidrug resistance in human breast cancer cells. Proc Natl Acad Sci USA 85:582-586
16. Ford JM, Prozialeck WC, Hait WN (1989) Structural features determining activity of phenothiazines and related drugs of inhibition of cell growth and reversal of multidrug resistance. Mol Pharmacol 35:105-115
17. Ford JM, Bruggeman EP, Pastan I, Gottesmann M, Hait WN (1990) Cellular and biochemical characterization of thioxanthenes for reversal of multidrug resistance in human and murine cell lines. Cancer Res 50:1748-1756
18. Ford JM, Yang JM, Hait WN (1991) Effect of buthionine sulfoximine on toxicity of verapamil and doxorubicin to multidrug resistant cells and to mice. Cancer Res 52:67-72
19. Garnier-Suillerot A, Borrel MN, Pereira E, Fiallo M (1994) Analysis in lung cells of the P-glycoprotein associated efflux of anthracyclines and of its inhibition by different classes of molecules. Anti-Cancer Drugs 5[Suppl 1]:30
20. Goormaghtigh E, Chatelain P, Casperas J, Ruysschaert JM (1980) Evidence of a specific complex between Adriamycin and negatively-charged phospholipids. Biochim Biophys Acta 597:1-14
21. Pawagi AB, Wang J, Silverman M, Reithmeier RA, Deber CM (1994) Transmembrane aromatic amino acid distribution in Pglycoprotein. A functional role in broad substrate specificity. J Mol Biol 235:554-564
22. Pearce HL, Winter MA, Beck WT (1990) Structural characteristics of compounds that modulate P-glycoprotein-associated multidrug resistance. Adv Enzyme Regul 30:357-373
23. Ramu A (1989) Structure-activity relationship of compounds that restore sensitivity to doxorubicin in drug-resistant P388 cells. In: Kessel D (ed) Resistance to antineoplastic drugs. CRC, Boca Raton, Fla, pp 63-80